MRK dividend yield: 3.25%. GILD dividend yield: 4.00%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. GILD is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in GILD shares.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
GILD is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in GILD shares.
Is MRK or GILD better for dividend income in 2026?
MRK currently offers a 3.25% yield (3.08/share/year) while GILD offers 4.00% (2.00/share/year). GILD provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs GILD earn per year?
With $10,000 invested today: MRK pays approximately $325/year. GILD pays approximately $400/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $899/year (GILD).
Does MRK or GILD pay monthly dividends?
MRK pays quarterly dividends. GILD pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs GILD comparison by email
Save your analysis + get weekly dividend insights. Free forever.